Immunosuppressive Management of Cardiac Sarcoidosis


Topic

Procedure

N (% endorsing)

Indications for initiation of immunomodulatory therapy

(a) Hypermetabolic activity on a cardiac FDGPET scan

24 (77.4 %)

(b) Delayed enhancement on cardiac MRI

19 (61.3 %)

(c) Conduction defects

21 (67.7 %)

(d) LV dysfunction

24 (77.4 %)

(e) RV dysfunction in the absence of pulmonary hypertension

18 (58.1 %)

(f) Ventricular arrhythmias

24 (77.4 %)

(g) Atrial arrhythmias

13 (41.9 %)

(h) Other

7 (22.6 %)

Immunosuppressive therapies used in treating cardiac sarcoidosis

(a) Prednisone

30 (96.8 %)

(b) Methotrexate

12 (38.7 %)

(c) Azathioprine

6 (19.4 %)

(d) Mycophenolate mofetil

2 (6.5 %)

(e) Anti-TNF agent

5 (16.1 %)

(f) Other

5 (16.1 %)

Dose of prednisone used

(a) 20 mg

4 (12.9 %)

(b) 30–40 mg

14 (45.2 %)

(c) 60 mg

7 (22.6 %)

(d) 0.5 mg/kg/ideal body weight

3 (9.7 %)

(e) 1 mg/kg/ideal body weight

2 (6.5 %)

(f) I don’t use prednisone

0 (0 %)

(g) Other

2 (6.5 %)

Initiation of steroid sparing agent with corticosteroids

(a) No

11 (42.3 %)

(b) Yes

12 (46.2 %)

(c) Other

4 (15.4 %)

Does the initial dosage of steroids differ depending on indication (active arrhythmias versus cardiomyopathy)?

(a) No, I use the same dosing range no matter what the indication

19 (70.4 %)

(b) Yes, I choose a higher dose for arrhythmias

6 (22.2 %)

(c) Yes, I choose a higher dose for cardiomyopathy

3 (11.1 %)

(d) Other

2 (7.4 %)

Duration of immunosuppressive therapy

(a) 1 year

4 (14.8 %)

(b) 2 years

5 (18.5 %)

(c) Indefinitely

7 (25.9 %)

(d) Other

13 (48.1 %)

Does the duration of immunosuppressive therapy differ depending on indication (active arrhythmias versus cardiomyopathy)?

(a) No

18 (66.7 %)

(b) Yes

6 (22.2 %)

(c) Other

7 (25.9 %)


Bold = Agreement ≥70 %, Italics = agreement ≥50 % but <70 %

Abbreviations: FDGPET 18-fluorodeoxyglucose Positron Emission Testing, cMRI Cardiac Magnetic Resonance Imaging, LV Left Ventricular, RV Right Ventricular




Table 11.2
Agents commonly used in the management of sarcoidosis. None of the steroid-sparing agents have been studied in cardiac sarcoidosis























 
Recommended dose

Main side-effects

Monitoring needed

Comments

Prednisone

20–30 mg daily or equivalent to be tapered gradually over 6 months

Weight gain, increase blood sugar, hypertension, osteopenia/osteoporosis, infection, neuropsychiatric reactions, infections

Blood sugar, weight, blood pressure, bone density

Rapid-acting but has numerous short and long term side effects

Methotrexate [18]
< div class='tao-gold-member'>

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Jul 10, 2016 | Posted by in CARDIOLOGY | Comments Off on Immunosuppressive Management of Cardiac Sarcoidosis

Full access? Get Clinical Tree

Get Clinical Tree app for offline access